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CME
Diabetic and Nondiabetic Patients With
Left Main and/or 3-Vessel Coronary Artery Disease
Comparison of Outcomes With Cardiac Surgery and Paclitaxel-Eluting Stents
Adrian P. Banning, MD,* Stephen Westaby, MS, PHD,* Marie-Claude Morice, MD,†
A. Pieter Kappetein, MD, PHD,‡ Friedrich W. Mohr, MD,§ Sergio Berti, MD, Mattia Glauber, MD,
Mirle A. Kellett, MD,¶ Robert S. Kramer, MD,¶ Katrin Leadley, MD,# Keith D. Dawkins, MD,#
Patrick W. Serruys, MD, PHD‡
Oxford, United Kingdom; Massy, France; Rotterdam, the Netherlands, Leipzig, Germany; Massa, Italy,
Portland, Maine; and Natick, Massachusetts
Objectives This study was designed to compare contemporary surgical revascularization (coronary artery bypass graft sur-
gery [CABG]) versus TAXUS Express (Boston Scientific, Natick, Massachusetts) paclitaxel-eluting stents (PES) in
diabetic and nondiabetic patients with left main and/or 3-vessel disease.
Background Although the prevalence of diabetes mellitus is increasing, the optimal coronary revascularization strategy in
diabetic patients with complex multivessel disease remains controversial.
Methods The SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) study ran-
domly assigned 1,800 patients (452 with medically treated diabetes) to receive PES or CABG.
Results The overall 1-year major adverse cardiac and cerebrovascular event rate was higher among diabetic patients treated
with PES compared with CABG, but the revascularization method did not impact the death/stroke/myocardial infarc-
tion rate for nondiabetic patients (6.8% CABG vs. 6.8% PES, p  0.97) or for diabetic patients (10.3% CABG vs.
10.1% PES, p  0.96). The presence of diabetes was associated with significantly increased mortality after either
revascularization treatment. The incidence of stroke was higher among nondiabetic patients after CABG (2.2% vs.
PES 0.5%, p  0.006). Compared with CABG, mortality was higher after PES use for diabetic patients with highly
complex lesions (4.1% vs. 13.5%, p  0.04). Revascularization with PES resulted in higher repeat revascularization
for nondiabetic patients (5.7% vs. 11.1%, p  0.001) and diabetic patients (6.4% vs. 20.3%, p  0.001).
Conclusions Subgroup analyses suggest that the 1-year major adverse cardiac and cerebrovascular event rate is higher
among diabetic patients with left main and/or 3-vessel disease treated with PES compared with CABG, driven by
an increase in repeat revascularization. However, the composite safety end point (death/stroke/myocardial in-
farction) is comparable between the 2 treatment options for diabetic and nondiabetic patients. Although further
study is needed, these exploratory results may extend the evidence for PES use in selected patients with less
complex left main and/or 3-vessel lesions. (SYNergy Between PCI With TAXus and Cardiac Surgery [SYNTAX];
NCT00114972) (J Am Coll Cardiol 2010;55:1067–75) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.057p
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Kiabetes mellitus is a common life-threatening illness of
ncreasing prevalence. More than 171 million (2.8%) people
re currently diagnosed worldwide, with a projected increase to
66 million (4.4%) by 2030 (1). Diabetes increases the risk of
eveloping cardiovascular disease (2), and is a consistent
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lthough drug-eluting stents (DES) reduce restenosis in
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Diabetes Results From the SYNTAX Randomized Trial March 16, 2010:1067–75comparison with bare-metal stents
in diabetic patients (5), DES stud-
ies have consistently shown higher
repeat revascularization rates after
percutaneous coronary interven-
tion (PCI) compared with surgical
revascularization (6–11). How-
ever, most prior studies comparing
DES with surgery in diabetic pa-
tients have studied a limited range
of lesion complexity, were not ran-
domized, and typically did not dis-
tinguish between DES types (i.e.,
sirolimus versus paclitaxel).
In randomized controlled trials
of patients with less complex 1-
and 2-vessel disease, 4-year repeat
revascularization rates in patients
treated with paclitaxel-eluting
tents (PES) were similar for diabetic and nondiabetic patients
12). The SYNTAX (SYNergy between percutaneous coro-
ary intervention with TAXus and cardiac surgery) study is the
rst to compare coronary artery bypass graft surgery (CABG)
nd the TAXUS Express PES (Boston Scientific, Natick,
assachusetts) in nondiabetic and diabetic patients with com-
lex left main and/or 3-vessel disease.
ethods
tudy design and device description. The SYNTAX trial
s a prospective, 85-center clinical trial (13,14). Patients with de
ovo left main and/or 3-vessel disease were randomly allocated
:1 to either the TAXUS Express PES or CABG, with a priori
tratification based on the presence or absence of medically
reated diabetes and left main disease. Exploratory subgroup
nalysis of patients with medically treated diabetes was pre-
pecified per study protocol; no formal statistical hypotheses
ere defined a priori to test for superiority or noninferiority
etween CABG and PES in diabetic patients.
The institutional review board at each participating center
pproved the protocol, and all patients provided written con-
ent. The protocol and consent forms were consistent with the
nternational Conference on Harmonisation Guidance for
ndustry E6 Good Clinical Practice, the Declaration of Hel-
inki, and all local regulations, as appropriate. The study is
egistered on the National Institutes of Health website as
dentifier NCT00114972.
efinitions. For the primary analysis, medically treated dia-
etes was defined as treatment with oral hypoglycemic agents
r insulin at the time of enrollment in accordance with prior
tudies (12,15–17). Further analyses of all patients with diabetes
included those treated by diet alone) and with fasting plasma
lucose 126 mg/dl (7.0 mmol/l) were also conducted. Major
dverse cardiac and cerebrovascular events (MACCE) in-
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft surgery
CVA  cerebrovascular
accident
DES  drug-eluting stent(s)
MACCE  major adverse
cardiac and
cerebrovascular event
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
TIA  transient ischemic
attackluded a composite of all-cause death, cerebrovascular accident aCVA), MI, or repeat revascularization (any subsequent PCI
r CABG procedure in any coronary vessel) (14).
tatistical methods. Analysis of the intent-to-treat sample
as conducted using SAS system software, version 8.0 or
igher (SAS Institute, Cary, North Carolina). Data are
ummarized using descriptive statistics, presented as pro-
ortions (%, count/sample size) or mean SD. Continuous
ariables were compared with the use of the Student t test;
ifferences in discrete variables were assessed by means of
he chi-square test or Fisher exact test, as appropriate. The
values for interaction between diabetic status and treat-
ent were generated by logistic regression. Binary 12-
onth MACCE rates were reported by SYNTAX score
ercile for coronary anatomic complexity (low 22, inter-
ediate 23 to 32, and high 33) (18). Logistic regression
as used to determine predictors of composite death/
VA/MI and repeat revascularization in diabetic and non-
iabetic patients (see Online Supplement).
esults
atients included in the analysis. Of the 1,800 patients with
eft main (isolated or in addition to 1-, 2-, or 3-vessel disease) or
solated 3-vessel disease randomly allocated into SYNTAX,
52 (221 CABG, 231 PES) had medically treated diabetes. An
dditional 59 patients with diabetes treated by diet alone were
ncluded in the nondiabetic group (n  1,348). Among
atients with medically treated diabetes, 182 (40.3%) were
reated with insulin, and 270 (59.7%) were treated with oral
ypoglycemic agents only. Type 2 diabetes accounted for 94%
f patients with medically treated diabetes. One-year
ACCE was evaluated in 849 (94.6%) CABG patients (645
ondiabetic and 204 with medically treated diabetes) and 891
98.7%) PES patients (664 nondiabetic and 227 with
edically-treated diabetes). While pre-specified, these sub-
roup analyses are intended to be observational and hypothesis
enerating, as the primary end point was not met.
atient demographic, lesion, and procedural characteristics.
atient baseline and lesion characteristics were relatively well
atched in the SYNTAX randomized cohort (14) and be-
ween patients with medically treated diabetes and patients
reated with either CABG and PES, with the exception of
ncreased incidence of high triglycerides (150 mg/dl) in
ABG compared with PES (47.1% vs. 37.0%, p  0.04) and
ncreased incidence of elevated blood pressure 130/85 mm
g in PES (65.2% vs. 74.5%, p  0.03). In nondiabetic
atients, there were no significant differences in baseline
atient or lesion characteristics, with the exception of a higher
ncidence of smoking (70.5% vs. 60.7%, p  0.001), triglycer-
des 150 mg/dl (36.0% vs. 30.6%, p  0.046), and high-
ensity lipoprotein 40 mg/dl male or 50 mg/dl female
48.6% vs. 42.3%, p 0.03) in CABG patients compared with
ES patients.
Overall, compared with nondiabetic patients, diabetic
atients had increased incidence of comorbid risk factors
nd increased lesion complexity (Table 1).
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March 16, 2010:1067–75 Diabetes Results From the SYNTAX Randomized TrialAverage procedure time was 3.5  1.2 h and 1.7  0.9 h
n the CABG and PES groups, respectively (p  0.001), in
atients with diabetes, and 3.4  1.1 h and 1.7  0.9 h,
espectively, in patients without diabetes (p  0.001).
The rate of complete revascularization in the PES
roup was lower among diabetic (49.1%) compared with
ondiabetic patients (59.3%, p  0.007) whereas among
ABG-treated patients, complete revascularization was
omparable for diabetic (60.7%) and nondiabetic (64.0%)
atients (p  0.39).
edication use. For patients treated with PES, glyco-
Baseline Patient Demographics and Lesion CharTable 1 Baseline Patient Demographics and
Age, yrs
Male
Comorbid risk factors
Body mass index (kg/m2)
Metabolic syndrome*
Increased waist circumference
Triglycerides 150 mg/dl†
Low high-density lipoprotein†
Blood pressure 130/85 mm Hg
Fasting glucose 110 mg/dl
HbA1c 7.0%†
Hyperlipidemia
Cardiac history
Current smoker
Prior MI
Congestive heart failure
Chronic obstructive pulmonary disease
Carotid artery disease
Prior CVA
Prior TIA
Peripheral vascular disease
Creatinine 200 mol/l
Unstable angina
Left ventricular ejection fraction 30%‡
Lesion complexity
Diffuse disease or small vessels†
Average implanted stent diameter (PES only), mm
Total stent length (PES only), mm
EuroSCORE (26)
Parsonnet score (27)
SYNTAX score† (18)
Number of lesions†
Left main, any†
Left main only
Left main  1 vessel
Left main  2 vessels
Left main  3 vessels
3-vessel disease only†
Values are shown as mean SD (N) or % (n/N) *Metabolic syndrome d
or 35 inches female; 2) triglycerides 150 mg/dl; 3) high-density
130/85 mm Hg; and 5) fasting glucose 110 mg/dl (28). †Core
available.
CVA  cerebrovascular accident; EuroSCORE  European System
myocardial infarction; PES  paclitaxel-eluting stent(s); TIA  transierotein IIb/IIIa inhibitors (abciximab, eptifibatide, or tiro- Cban) were used in 34.3% (79 of 230) and 35.4% (236 of
66) of diabetic and nondiabetic patients, respectively.
tatin use at baseline was balanced between CABG and
ES patients in both diabetic patients (71.5% vs. 71.0%,
 0.91) and nondiabetic patients (76.6% vs. 75.3%, p 
.57). However, at discharge, statin use was significantly
ower in the CABG group for both diabetic patients (73.8%
s. 83.0%, p  0.02) and nondiabetic patients (74.7% vs.
8.0%, p  0.001). Thienopyridine antiplatelet use at
-year post-procedure was 19.0% and 71.8% in diabetic
atients and 13.8% and 70.8% in nondiabetic patients, the
risticson Characteristics
ondiabetic
n  1,348)
Diabetic
(n  452) p Value
 9.9 (1,348) 65.4 9.2 (452) 0.41
(1,077/1,348) 71.0 (321/452) 0.001
 4.4 (1,347) 29.5 5.2 (452) 0.001
(398/1,064) 69.9 (258/369) 0.001
(502/1,194) 60.6 (238/393) 0.001
(409/1,230) 41.7 (170/408) 0.002
(544/1,199) 61.2 (238/389) 0.001
(880/1,348) 69.9 (316/452) 0.07
(260/934) 82.2 (286/348) 0.001
(31/1,179) 56.9 (215/378) 0.001
(1,029/1,341) 81.5 (362/444) 0.03
(292/1,343) 15.8 (71/450) 0.006
(442/1,333) 32.0 (143/447) 0.65
(50/1,334) 7.4 (33/444) 0.001
(109/1,348) 10.0 (45/452) 0.22
(99/1,348) 10.8 (49/452) 0.02
(51/1,341) 6.0 (27/448) 0.046
(58/1,341) 5.8 (26/448) 0.20
(111/1,348) 14.6 (66/452) 0.001
(13/1,348) 2.9 (13/452) 0.003
(378/1,348) 29.6 (134/452) 0.51
(21/1,348) 2.9 (13/452) 0.07
(136/1,338) 13.4 (60/449) 0.06
 0.5 3.4 0.5 0.001
 47.5 88.6 49.0 0.37
 2.6 (1,348) 4.0 2.7 (452) 0.03
 6.8 (1,348) 11.3 6.4 (452) 0.001
 11.5 (1,340) 29.0 11.2 (449) 0.52
 1.8 (1,340) 4.6 1.8 (449) 0.003
(480/1,338) 29.0 (130/449) 0.007
(52/1,338) 2.2 (10/449) 0.10
(75/1,338) 4.0 (18/449) 0.19
(160/1,338) 11.1 (50/449) 0.64
(193/1,338) 11.6 (52/449) 0.13
(858/1,338) 71.0 (319/449) 0.007
s at least 3 of the following: 1) waist circumference40 inches male
ein 40 mg/dl in males or 50 mg/dl females; 4) blood pressure
ry reported. ‡Or indicated by clinical site as “poor” if exact value not
rdiac Operative Risk Evaluation; HbA1c  hemoglobin A1c; MI 
mic attack.acteLesi
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as been reported elsewhere (14).
-year clinical results in nondiabetic and diabetic
atients. One-year outcomes comparing CABG versus PES
reatment in diabetic and nondiabetic patients and binary
egression interaction effects at 1 year between diabetic status
nd treatment arm are shown in Table 2. In diabetic patients,
he 1-year composite MACCE rate was significantly higher
fter PES treatment compared with CABG treatment. In
ondiabetic patients, MACCE was slightly higher in the PES
roup compared with the CABG group, but the difference was
ot statistically significant. The number needed to treat by
ABG to avoid 1 MACCE event is 9 for diabetic patients and
1 for nondiabetic patients.
There were no statistically significant differences between
he CABG and PES groups in the composite safety end point
f death/CVA/MI, or in symptomatic graft occlusion or stent
hrombosis for either diabetic or nondiabetic patients. The
reatment by diabetes status interaction p value for death/
VA/MI was 0.98. Mortality was significantly higher among
iabetic versus nondiabetic patients after both PES (p 
.001) and CABG (p  0.01) treatments, with no significant
nteraction between treatment arm and diabetes status. In
ondiabetic patients, the CVA rate was higher after CABG
ompared with PES treatment; this effect did not reach
tatistical significance in diabetic patients, possibly because of
he small sample size in that group.
Repeat revascularization (PCI or CABG in any vessel) was
ignificantly higher in the PES group compared with the
ABG group in both diabetic and nondiabetic patients,
riving the statistically significant increase in composite
ACCE in PES-treated diabetic patients. The majority of
epeat revascularizations in PES-treated patients was by PCI.
imilar results were seen in an overall diabetic cohort that
ncluded diet-treated patients and when diabetes was defined
s fasting plasma glucose 126 mg/dl (data not shown).
Repeat revascularization was significantly higher in dia-
etic versus nondiabetic patients after PES treatment (p 
.001) but not CABG treatment (p  0.74). Medically
reated diabetes was a significant independent predictor of
epeat revascularization in the PES arm (odds ratio: 2.93,
5% confidence interval: 1.69 to 5.08, p  0.001), but not
n the CABG arm (Online Supplement A). The interaction
value for the effect of diabetes status by treatment arm on
epeat revascularization was 0.13. For patients with medi-
ally treated diabetes, PES treatment was a significant
redictor of repeat revascularization but not death/
VA/MI (Online Supplement A).
Degree of pre-procedure glycemic control was not a
ignificant predictor of 1-year outcomes for diabetic pa-
ients, and differences between the CABG and PES arms
ere similar regardless of whether patients had good or poor
lycemic control (Online Supplement B).
nsulin- versus noninsulin-requiring diabetic patients.
iabetic patients treated with insulin (n  182) had areater incidence of several comorbid risk factors compared 1-
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March 16, 2010:1067–75 Diabetes Results From the SYNTAX Randomized Trialith diabetic patients treated only with oral hypoglycemic
gents (n  270), including increased baseline rates of prior
I (39.7% vs. 26.9%, p  0.005), peripheral vascular
isease (20.3% vs. 10.7%, p  0.005), and hemoglobin A1c
7.0% (77.1% vs. 43.1%, p  0.001). However, other
aseline characteristics examined were relatively well
atched between insulin-treated and noninsulin-treated
iabetic patients.
There were no significant differences in death, MI, or
VA between the PES and CABG groups in either the oral
ypoglycemic-treated or insulin-treated diabetic patients
Table 3); however, the insulin status by treatment group
nteraction term for composite death/CVA/MI was 0.06,
ith higher rates in the CABG arm for diabetic patients
aking oral medications, and higher rates in the PES arm for
nsulin-treated patients. The mortality rate for PES-treated
nsulin-requiring diabetic patients (12.5%) was nonsignifi-
antly higher than for CABG-treated insulin-requiring
iabetic patients (5.7%, p  0.12) and PES-treated diabetic
atients receiving oral medications (5.8%, p  0.07). In the
ABG arm, mortality rates were comparable between
iabetic patients taking oral medications and patients taking
nsulin (p  0.75) (rates listed in Table 3).
As was seen in the overall diabetic cohort, repeat revascu-
arization rates were higher in the PES arm versus the CABG
rm in both the oral hypoglycemic-treated and the insulin-
reated diabetic patients. However, within each treatment arm,
epeat revascularization rates were comparable regardless of
hether insulin was required (PES: 20.5% insulin vs. 20.1%
ral hypoglycemic agents, p  0.95; CABG: 9.2% insulin vs.
.3% oral hypoglycemic agents, p  0.15).
ffect of lesion complexity on outcomes in patients with
iabetes. The SYNTAX score (18) grades the angio-
raphic lesion complexity of coronary disease to provide an
vidence-based tool for selecting the optimal revasculariza-
ion strategy (CABG or PCI).
There were no significant differences in composite safety
death/CVA/MI) between the PES and CABG groups in
ny SYNTAX score tercile in either diabetic (Fig. 1) or
ondiabetic (Fig. 2) patients. Patients with higher SYNTAX
cores had increased repeat revascularization after PES
reatment compared with CABG, driving increased
ACCE, particularly for diabetic patients. However, for
atients in the lowest SYNTAX score tercile, MACCE was
ot significantly different between treatments arms, with
omparable repeat revascularization between the CABG
nd PES groups in nondiabetic patients. For PES-treated
atients, mortality rates increased with increasing SYNTAX
cores such that in patients with the highest lesion complexity
SYNTAX scores 33) mortality was significantly increased
ompared with CABG for both diabetic and nondiabetic
atients. The mortality interaction term for treatment group by
YNTAX score tercile is p  0.15 for patients with diabetes
nd p  0.05 for patients without diabetes. 1-
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he patients enrolled in the SYNTAX trial, which included
nly patients with left main and/or 3-vessel disease, are the
ost complex ever studied in a coronary artery revascular-
zation trial. Among patients with medically treated diabe-
es in the SYNTAX trial, 71.0% were treated for 3-vessel
isease and 29.0% for left main disease; furthermore, 78.5%
f patients with left main disease had concurrent 2- or
-vessel disease. Thus, it is important to interpret the results
f this study in the context of the high-risk conditions
ncluded. Furthermore, as the primary end point of the
Figure 1 Diabetic Patient Outcomes According to SYNTAX Sco
One-year rates of (A) composite death/cerebrovascular accident (CVA)/myocardial
vascular events (MACCE), (E) CVA, and (F) all-cause death in diabetic patients tre
(PES). Rates are separated by the SYNTAX study scores indicating low (0 to 22), mverall SYNTAX study was not met (14), these observa- aional subgroup results are to be considered hypothetical and
ypotheses generating only, and should not necessarily
ictate any change in current practice patterns.
At 1 year, the key findings of this observational pre-defined
ubgroup analysis are as follows. 1) In patients with left
ain and/or 3-vessel disease, MACCE rates were signifi-
antly higher in the PES arm compared with the CABG
rm in diabetic patients, and directionally higher (but
onsignificant) in nondiabetic patients. Although there was
o statistically powered pre-specified primary end point of
his subgroup analysis, this result suggests that MACCE
rcile
tion (MI), (B) MI, (C) revascularization, (D) major adverse cardiac and cerebro-
ith coronary artery bypass graft surgery (CABG) or TAXUS paclitaxel-eluting stents
(23 to 32), and high (33) anatomic lesion complexity.re Te
infarc
ated w
ediumfter PES treatment might be inferior to CABG treatment
f
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March 16, 2010:1067–75 Diabetes Results From the SYNTAX Randomized Trialor diabetic patients with left main and/or 3-vessel disease.
) There were no significant differences in composite
eath/CVA/MI or in the individual components of death or
I between the CABG and PES groups regardless of
iabetic status or lesion complexity. Compared with non-
iabetic patients, patients with diabetes had increased mor-
ality in both the CABG and PES groups. 3) In both
iabetic and nondiabetic patients with the greatest anatom-
cal complexity (SYNTAX scores 33), mortality was
ignificantly increased with PES treatment compared with
ABG. 4) Repeat revascularization was higher with PES
ompared with CABG in both diabetic and nondiabetic
Figure 2 Nondiabetic Patient Outcomes According to SYNTAX
See the legend to Figure 1 for further descriptive details and abbreviations.atients. 5) Patients with diabetes had significantly increased lepeat revascularization rates compared with nondiabetic pa-
ients when treated with PES, but not when treated with
ABG. 6) Repeat revascularization rates after PES treatment
and hence the relative difference between the PES and CABG
roups) tended to increase with increasing lesion complexity
i.e., higher SYNTAX score), particularly in patients with
iabetes; in nondiabetic patients with low lesion complexity,
epeat revascularization rates were similar between treatment
rms. These analyses were consistent with an analysis of all
atients diagnosed with diabetes at enrollment (including those
ot receiving medical treatment; data not shown).
This analysis confirms prior studies of diabetic patients with
TercileScoreess complex multivessel disease that show no difference in
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Diabetes Results From the SYNTAX Randomized Trial March 16, 2010:1067–75ortality between CABG and DES patients overall (6–
0,19); however, diabetic compared with nondiabetic patients
ad increased mortality after either PES or CABG, demon-
trating that neither treatment option can eliminate the in-
reased mortality risk conferred by diabetes (2). The mortality
ate in PES-treated diabetic patients requiring insulin was
2.5%, compared with 5.7% in CABG-treated patients taking
nsulin and 5.8% in PES-treated diabetic patients taking oral
edications, although this difference did not reach statistical
ignificance. While the sample sizes in these groups are too
mall to allow firm conclusions and there was no significant
nteraction effect for mortality between diabetes status and
reatment arm, this finding may warrant further study. This
ffect was also seen in a study comparing diabetic versus
ondiabetic patients treated with DES for unprotected left
ain disease (20). In addition, in patients with highly complex
eft main and/or 3-vessel lesions (SYNTAX scores 33),
ortality was increased in the PES group compared with the
ABG group, with a significant SYNTAX score by treatment
rm interaction term in nondiabetic patients and an interaction
value of 0.15 in diabetic patients. This finding is not
nexpected, given that lesion complexity does not impact
echnical success with CABG as it does with PCI, and that
CI does not prevent ischemia due to disease progression
utside the stented segment.
Published studies have demonstrated higher DES repeat
evascularization rates compared with CABG (6–11), an
ffect that was replicated in the SYNTAX study. The
elative risk of repeat revascularization of PES over CABG
as 3.18 (95% confidence interval: 1.77 to 5.71) in diabetic
atients compared with 1.94 (95% confidence interval: 1.33
o 2.84) in nondiabetic patients. While the interaction term
or diabetes status by treatment arm for revascularization
as p  0.13, p values 0.10 may not necessarily rule out
he possibility of a meaningful interaction, due at least in
art to the low power of the test (21).
Prior studies of PES usage in randomized trials suggest that
n patients with mainly 1- and 2-vessel disease, angiographic
estenosis and target lesion revascularization rates are compa-
able in diabetic and nondiabetic patients after PES implanta-
ion (12,15,16,22). In contrast, the SYNTAX study results
emonstrate that in diabetic patients with highly complex
-vessel and/or left main disease (a population not previously
tudied in DES randomized trials), revascularization is higher
n diabetic than in nondiabetic patients treated with PES. It is
mportant to note that by definition, repeat revascularization in
he SYNTAX study included revascularization in any vessel,
ot just a single target vessel or lesion revascularization as in
rior studies. In this regard, it is likely that aggressive progres-
ion of diffuse disease in patients with diabetes will impact the
ES cohort more noticeably than the CABG group, in which
rafts placed distally minimize the impact of progressive
isease in the entire upstream proximal vessel.
Results similar to those of the SYNTAX study were seen in
he CARDia (Coronary Artery Revascularization in Diabetes)
nd ARTS II (Arterial Revascularization Therapies Study– tart II) studies comparing sirolimus-eluting stents to CABG
n diabetic patients with multivessel disease (8,23). In the
ARDia study (23), 1-year death/CVA/MI in DES-treated
iabetic patients (11.6%) was comparable to that in CABG-
reated diabetic patients (12.4%), whereas revascularization was
ignificantly higher in the DES arm compared with CABG. In
omparison to the present results, it is also important to note
hat the primary end point of the CARDia study (death/CVA/
I) did not include revascularization, which was included in
he SYNTAX study primary MACCE end point.
This study also demonstrated that diabetic patients with
ore complex coronary disease, as reflected by higher
YNTAX scores, tended to have increased repeat revascu-
arization rates when treated with PES, driving differences
n total MACCE. Again, this is likely due to accelerated
isease progression in diabetic patients, which would influ-
nce repeat revascularization rates in the PES arm but not in
he CABG arm. Nondiabetic patients with the lowest
ngiographic complexity had similar repeat revascularization
ates in both treatment arms. Thus, accelerated atheroma,
he active inflammatory process, and increased lesion com-
lexity may all underlie the observed differences between the
ABG and PES groups in diabetic patients.
tudy limitations. There are several important limitations
o consider when interpreting the results of this study. First,
ollow-up at 1 year may not yet reflect the true long-term
ifferences between CABG and PES treatments of diabetic
atients based on the previously reported BARI (Bypass
ngioplasty Revascularization Investigation) study (24) that
emonstrated reduced long-term mortality in CABG com-
ared with balloon angioplasty; the SYNTAX study
ollow-up to 5 years is ongoing. Second, although pre-
pecified, these subgroup analyses are intended to be obser-
ational and hypothesis generating because of the small
amples sizes and event numbers in the subgroups analyzed.
hird, fasting glucose and hemoglobin A1c levels were
vailable at baseline only; glycemic control information and
ubsequent diagnoses of diabetes during the course of
ollow-up are unknown. Fourth, although the patients
ncluded in the BARI-2D study (25) are not comparable to
atients enrolled in the SYNTAX study (BARI-2D enroll-
ent was limited primarily to stable angina with only 21%
ultivessel disease, and only 35% DES use in the PCI arm),
he SYNTAX study did not include an optimal medical
herapy arm with which to compare to such analyses (although
edical therapy alone would not be appropriate for the
dvanced multivessel atherosclerotic disease in most of the
YNTAX trial patients). Finally, because the SYNTAX study
nrolled only patients with left main and/or 3-vessel disease,
iabetic patients in this study may not be typical of all diabetic
atients undergoing coronary revascularization procedures. In
ddition, the low percentage of patients with diffuse disease
nd small vessel lesions in the diabetes cohort may indicate that
his sample is not representative of a typical population of
atients with diabetes. Other study limitations not specific to
he diabetes subanalysis have been reported previously (14).
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1075JACC Vol. 55, No. 11, 2010 Banning et al.
March 16, 2010:1067–75 Diabetes Results From the SYNTAX Randomized Trialonclusions
hese 1-year SYNTAX results suggest that in patients with
eft main and/or 3-vessel disease, MACCE is increased for
ES-treated diabetic patients compared with CABG-treated
atients, driven by an increase in repeat revascularization.
omposite safety and mortality end points are comparable
etween the CABG and PES arms. Although further study is
eeded, these exploratory results may extend the evidence base
or DES use (particularly PES) in selected diabetic and
ondiabetic patients with left main and/or 3-vessel disease.
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